Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Anthony GONCALVES"'
Autor:
François Bertucci, Florence Lerebours, Michele Ceccarelli, Arnaud Guille, Najeeb Syed, Pascal Finetti, José Adélaïde, Steven Van Laere, Anthony Goncalves, Patrice Viens, Daniel Birnbaum, Emilie Mamessier, Céline Callens, Davide Bedognetti
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Inflammatory breast cancer (IBC) is the most pro-metastatic form of BC. Better understanding of its enigmatic pathophysiology is crucial. We report here the largest whole-exome sequencing (WES) study of clinical IBC samples. Metho
Externí odkaz:
https://doaj.org/article/d411209f682649f3b4011eb089a7cbba
Autor:
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) is a dose-finding phase I and a randomized phase II, open-label trial evaluating
Externí odkaz:
https://doaj.org/article/50f0c9a693404d0bbb0bf5ae3d4ee9c1
Autor:
Yasmine Rhanine, Hervé Bonnefoi, Anthony Goncalves, Marc Debled, Sylvestre Le Moulec, Nathalie Bonichon, Gaetan Macgrogan, Monica Arnedos, Bénédicte Dubroca-Dehez, Thomas Grellety
Publikováno v:
Breast, Vol 73, Iss , Pp 103667- (2024)
Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life.The primary end-point was CBR at 6 months. Twenty-four patien
Externí odkaz:
https://doaj.org/article/344b27159eb14ac881aa9320bdf6aea4
Autor:
Antoine Vasseur, Matthieu Carton, Severine Guiu, Paule Augereau, Lionel Uwer, Marie-Ange Mouret-Reynier, Christelle Levy, Jean-Christophe Eymard, Jean-Marc Ferrero, Marianne Leheurteur, Anthony Goncalves, Marie Robert, Thibault De La Motte Rouge, Thomas Bachelot, Thierry Petit, Marc Debled, Thomas Grinda, Isabelle Desmoulins, Laurence Vanlemmens, Vincent Nicolaï, Gaëtane Simon, Luc Cabel
Publikováno v:
Breast, Vol 65, Iss , Pp 136-144 (2022)
Background: Taxanes are one of the most effective chemotherapies (CT) in breast cancer (BC), but the efficacy of taxanes rechallenge in early metastatic relapse has been poorly studied in patients previously treated by taxanes in the (neo)adjuvant se
Externí odkaz:
https://doaj.org/article/3e5e3d1b6d254f9091fd5376422aa2e4
Autor:
Guillaume Berton, Cécile Vicier, Marie-Anne Hospital, Colombe Saillard, Yosr Hicheri, Valerio Maisano, Ferdinand Villetard, Camille Rouzaud, Evelyne D’incan Corda, Jerome Rey, Bilal Mohty, Aude Charbonnier, Aurelien Proux, Norbert Vey, Anthony Goncalves, Sylvain Garciaz
Publikováno v:
HemaSphere, Vol 7, p e4520163 (2023)
Externí odkaz:
https://doaj.org/article/301143d94eb6467fa8b3cb884f0b6126
Autor:
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/1872bd3c329443328fa10ee0e5e38651
Autor:
Fabien Moinard-Butot, Caroline Saint-Martin, Carole Pflumio, Matthieu Carton, William Jacot, Paul-Henri Cottu, Véronique Diéras, Florence Dalenc, Anthony Goncalves, Marc Debled, Anne Patsouris, Marie-Ange Mouret-Reynier, Laurence Vanlemmens, Marianne Leheurteur, George Emile, Jean-Marc Ferrero, Isabelle Desmoulins, Lionel Uwer, Jean-Christophe Eymard, Bianca Cheaib, Coralie Courtinard, Thomas Bachelot, Michaël Chevrot, Thierry Petit
Publikováno v:
Breast, Vol 63, Iss , Pp 54-60 (2022)
Purpose: Trastuzumab-emtansine (T-DM1), as well as lapatinib plus capecitabine were proven effective in two Phase III studies, following first-line trastuzumab plus a taxane. The introduction of dual HER2 blockade by trastuzumab and pertuzumab as fir
Externí odkaz:
https://doaj.org/article/91f75990af2445a0a8def40ce2143a62
Autor:
Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guille, Nadine Carbuccia, Nicolas Isambert, Florence Dalenc, Marie Robert, Christelle Levy, Jihane Pakradouni, José Adelaïde, Max Chaffanet, Patrick Sfumato, Emilie Mamessier, François Bertucci, Anthony Goncalves
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 2057-2070 (2022)
The phosphatidylinositol‐3‐kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is frequently activated in HER2‐negative breast cancer and may play a role in taxane resistance. The phase IB/II TAKTIC trial (NCT01980277) has shown that
Externí odkaz:
https://doaj.org/article/703ca5faef324c5b808393f820024f09
Autor:
Mylène Annonay, MD, Lisa Gauquelin, MD, Romain Geiss, MD, Mony Ung, MD, Laurence Cristol-Dalstein, MD, Marie-Ange Mouret-Reynier, MD PHD, Anthony Goncalves, MD PHD, Sophie Abadie-Lacourtoisie, MD, Eric Francois, MD, Christophe Perrin, MD, Johan Le Fel, MD, Véronique Lorgis, MD, Véronique Servent, MD, Lionel Uwer, MD, Christelle Jouannaud, MD, Marianne Leheurteur, MD, Florence Joly, MD PHD, Loic Campion, MD, Coralie Courtinard, MPH, Olivier Villacroux, MD, Thierry Petit, MD PHD, Pierre Soubeyran, MD, Catherine Terret, MD, Carine Bellera, PHD, Etienne Brain, MD PHD, Suzette Delaloge, MD MPH
Publikováno v:
Breast, Vol 60, Iss , Pp 138-146 (2021)
Background: Treatment and outcomes of patients with HER2-positive (HER2+) metastatic breast cancer (MBC) have dramatically improved over the past 20 years. This work evaluated treatment patterns and outcomes according to age. Methods: Women who initi
Externí odkaz:
https://doaj.org/article/ade3e6c3b78e4adab88c10f438f12991
Autor:
Amanda Bortolini Silveira, François-Clément Bidard, Marie-Laure Tanguy, Elodie Girard, Olivier Trédan, Coraline Dubot, William Jacot, Anthony Goncalves, Marc Debled, Christelle Levy, Jean-Marc Ferrero, Christelle Jouannaud, Maria Rios, Marie-Ange Mouret-Reynier, Florence Dalenc, Caroline Hego, Aurore Rampanou, Benoit Albaud, Sylvain Baulande, Frédérique Berger, Jérôme Lemonnier, Shufang Renault, Isabelle Desmoulins, Charlotte Proudhon, Jean-Yves Pierga
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are two cancer-derived blood biomarkers that inform on patient prognosis and treatment efficacy in breast cancer. We prospectively evaluated the clinical validity of quantifyin
Externí odkaz:
https://doaj.org/article/defc150529374d2a9813a467847b33d8